| Name | Title | Contact Details |
|---|
Trilix Marketing Group is a Johnston, IA-based company in the Business Services sector.
Dalkia Energy Solutions, a subsidiary of the EDF Group, specializes in energy-efficient technologies and services for commercial and industrial clients in the United States, Puerto Rico, and Canada. Founded in France in 1937, the company has a rich history in energy performance contracting, starting with the management of a hospital boiler operation. With around 15,000 employees and annual revenues of approximately $5 billion, Dalkia offers a variety of services. These include energy efficiency and management programs, energy performance contracts that guarantee savings, and the development of renewable energy sources like biomass and geothermal. The company also focuses on infrastructure modernization through its Smart Infrastructure Solutions division, enhancing public safety and energy efficiency. Additionally, Dalkia undertakes energy construction and maintenance projects to improve energy performance in industrial and commercial settings. Dalkia serves a diverse clientele, including large corporations, healthcare facilities, and public sector clients, providing tailored solutions that address local needs and sustainability challenges.
Innovative Marketing is a Jupiter, FL-based company in the Business Services sector.
The Atlantic Region/Assurity at Work is a Jacksonville, FL-based company in the Business Services sector.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.